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表１ Clinical Characteristics of Patients










１ ６１ M RAEB-Ⅱ ６．２ ２８７３０７６ ５．７ １５．０
２ ５２ M RAEB-Ⅱ ８．８ １５３０３８ ２．５ １４．０
３ ５５ M MDS-AML ６．９ １１００ ２．３ biopsy
４ ８３ M RAEB-Ⅱ ９．４ ５１４０４２ ０．８ １４．４
５ ７９ M MDS-AML ８．３ ４８３０６３ ０．６ ２８．０
６ ５９ M MDS-AML ６．１ ２３９０５０ ２．６ ３２．４
７ ６７ M RAEB-Ⅰ ７．７ ９１４０９４．５ ２３．３ ５．３
８ ７５ M RAEB-Ⅰ ５．０ ５１００３６ １．０ ８．８
９ ６４ M RAEB-Ⅱ ５．５ １９２０２６ ８．５ １９．３
１０ ５６ M RAEB-Ⅰ ６．１ ２２００４０ １．４ ９．５
１１ ６７ M RAEB-Ⅱ ６．８ ７２１０３５ ５．１ １６．０
１２ ６８ M MDS-AML ６．０ ３０５０２５ １．６ ４１．０
１３ ４７ M RAEB-Ⅰ ６．７ ２６８０１９．４ ２．３ ９．２
１４ ８１ M RAEB-Ⅰ ７．０ ６３００２９ ４２．７ ８．３
１５ ５７ M RAEB-Ⅱ ６．０ １３１０２２ １１．１ １５．５
１６ ７３ M MDS-AML ９．９ １４１０２４．２ ３．２ ３７．５
表２ IPSS score and risk group of Patients
Case Age/Sex Cytopenias＊ BM blasts
（%）
Karyotype† Score Risk group
１ ６１ M ２／３ １５．０ Poor ３．０ High
２ ５２ M ２／３ １４．０ Good ２．０ Int-２
３ ５５ M ２／３ biopsy Poor １．５ Int-２
４ ８３ M ２／３ １４．４ Good ２．０ Int-２
５ ７９ M ２／３ ２８．０ Good ２．５ High
６ ５９ M ２／３ ３２．４ Good ２．５ High
７ ６７ M ０／１ ５．３ Good ０．５ Int-１
８ ７５ M ２／３ ８．８ Poor ２．０ Int-２
９ ６４ M ２／３ １９．３ Good ２．０ Int-２
１０ ５６ M ２／３ ９．５ Poor ２．０ Int-２
１１ ６７ M ２／３ １６．０ Poor ３．０ High
１２ ６８ M ２／３ ４１．０ Poor ３．５ High
１３ ４７ M ２／３ ９．２ Good １．０ High
１４ ８１ M ０／１ ８．３ Poor １．５ Int-２
１５ ５７ M ２／３ １５．５ Intermediate ２．５ High
１６ ７３ M ２／３ ３７．５ Intermediate ３．０ High
＊０／１，no or１ cytopenias；２／３２or３ cytopenias
†Good, normal, -Y, del（５q）, del（２０q） ; Poor, complex（＞３
abnormalities）or chromosome７ anomalies ; Intermediate, other ab-
normalities
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表３ Clinical response of Patients
Case Age/Sex IPSS Risk courses Response
１ ６１ M ３．０ High １ NR
２ ５２ M ２．０ Int-２ １ NR
３ ５５ M １．５ Int-２ １ NR
４ ８３ M ２．０ Int-２ ２ NR
５ ７９ M ２．５ High ２ PR
６ ５９ M ２．５ High ３ NR
７ ６７ M ０．５ Int-１ ２ CR
８ ７５ M ２．０ Int-２ １ NR
９ ６４ M ２．０ Int-２ ４ PR
１０ ５６ M ２．０ Int-２ ２ NR
１１ ６７ M ３．０ High １ NR
１２ ６８ M ３．５ High １ NR
１３ ４７ M １．０ High ２ NR
１４ ８１ M １．５ Int-２ １ NR
１５ ５７ M ２．５ High ２ PR
１６ ７３ M ３．０ High ２ CR
表４ IPSS and response
IPSS Low Int-１ Int-２ High Total
CR １ １ ２
PR １ ２ ３
NR ６ ５ １１
Total １ ７ ８ １６
表５ BM blast and response
BM blast（％） ＜１０ １０－２０ ２０＜ Total
CR １ １ ２
PR ２ １ ３
NR ４ ４ ２ １＊ １１
Total ５ ６ ４ １＊ １６
＊Case３diagnosed by biopsy specimen
表６ Karyotype and response
Karyotypes Good Intermediate Poor Total
CR １ １ ２
PR ２ １ ３
NR ４ ７ １１
Total ７ ２ ７ １６
表７ Cytopenias and response
Cytopenias ０／１ ２／３ Total
CR １ １ ２
PR ３ ３
NR １ １０ １１
Total ２ １４ １６
図１ Overall survival
8 高リスク群骨髄異形成症候群（MDS）に対する低用
量 Ara-C + M-CSF療法の検討
Tokushima Red Cross Hospital Medical Journal

























































表８ Outcome of patients
Case Age/Sex Diagnosis IPSS Response Outcome
１ ６１ M RAEB-Ⅱ High NR ３M A
２ ５２ M RAEB-Ⅱ Int-２ NR ３M A
３ ５５ M MDS-AML Int-２ NR ４M D
４ ８３ M RAEB-Ⅱ Int-２ NR MDS→AML ６M A
５ ７９ M MDS-AML High PR １１M A
６ ５９ M MDS-AML High NR １０M D
７ ６７ M RAEB-Ⅰ Int-１ CR in CR ３８M A
８ ７５ M RAEB-Ⅰ Int-２ NR ６M D
９ ６４ M RAEB-Ⅱ Int-２ PR １６M A
１０ ５６ M RAEB-Ⅰ Int-２ NR CAG, RIST ２８M A
１１ ６７ M RAEB-Ⅱ High NR ２M D
１２ ６８ M MDS-AML High NR ５M D
１３ ４７ M RAEB-Ⅰ High NR ２０M D
１４ ８１ M RAEB-Ⅰ Int-２ NR １０M D
１５ ５７ M RAEB-Ⅱ High PR ９M D
１６ ７３ M MDS-AML High CR relapse１７M ３２M A
図２ Survival by response
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Treatment with Low-dose Ara-C Followed by Administration of Macrophage
Colony-Stimulating Factor in Patients with High-risk Groups of Myelodysplastic
Syndrome and its Leukemic Phase.
Keiji OZAKI, Tetsuya GOTO, Kazuhiro MIKI, Michiko ICHIMIYA, Osamu FUJINO, Ai MIHARA
Division of Hematology, Tokushima Red Cross Hospital
Myelodysplastic syndrome typically occurs in elderly people, and prognosis of its high-risk subgroups remains
unfavorable. None of the current treatment option other than hematopoietic stem cell transplantation has
curative potential. Aggressive chemotherapy can induce complete remission in some patients, but the incidence
of severe complications and morbidity is high, the majority of patients are not optimal candidate for these
therapies. Treatment with low-dose Ara-C followed by administration of M-CSF has low incidence of
complications and applicable for such cases. Sixteen patients with high-risk subgroups of MDS（RAEB Ⅰ, Ⅱ）
and leukemic phase（MDS-AML） who were admitted to Tokushima Red Cross Hospital from January２００１ to
December２００４, were included in the study. Therapy was consisted of Ara-C１５mg/m２×２per day subcutaneous
injection for １４ days, followed by administration of M-CSF８million units/day by intravenous infusion for
１４ days, repeatedly treated for １～４ courses. Median age of patients were ６５ years old. ５ patients were
classified as RAEB Ⅰ,６ as RAEB Ⅱ,５ as MDS-AML according to the WHO classification. The overall rate of
response to the treatment was３１．３％（５ patients）, including CR１２．５％（２ patients）, which were lower than
previous reported studies, whereas median survival（１９．６months）was almost equivalent. Two patients achieved
CR, one patient relapsed１７ months later and alive after３２ months, one alive in CR after３８ months. PR was
achieved in ３ patients, one died after ９ months, two alive and undergone supportive therapies. NR was
observed in １１ patients, ７ were died within ２０ months, ４ patients are alive in which contains one patient in
CR after reduced-intensity stem cell transplantation. Percent marrow blasts and numbers of cytopenias are not
correlated to the response. No cases with complicated chromosomal abnormality respond to the treatment.
Although in the NR patients, less requirement of blood transfusion were observed in some cases. These
observations suggest that low-dose Ara-C with M-CSF would also contribute to improvements in the quality of
life of patients.
Key words : myelodysplastic syndrome, acute myelogenous leukemia, cytosine arabinoside, macrophage colony-
stimulating factor（M-CSF）
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